REGULATORY

Chuikyo’s Draft Supplementary Opinions for 2020 Reimbursement Reform Calls for Medical Validity, Cost-Effective Analysis for Prescriptions

February 3, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) on January 31 presented a draft of supplementary opinions to be attached to the recommendations for the FY2020 medical fee revision at a general meeting of the Central Social Insurance Medical Council…

To read the full story

Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020
Chuikyo OKs Supplementary Opinions for 2020 Reimbursement Reform; No Mention on Health Coverage Review
February 6, 2020

REGULATORY

MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…